

Real-world experience with reversal of dabigatran by id

Thrombosis Research

197, 179-184

DOI: [10.1016/j.thromres.2020.11.010](https://doi.org/10.1016/j.thromres.2020.11.010)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Dabigatran etexilate/idarucizumab. Reactions Weekly, 2021, 1844, 145-145.	0.0	0
2	Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants. Journal of the American College of Cardiology, 2021, 77, 2987-3001.	1.2	69
3	Enhancement and evaluation of a prescription audit system for direct oral anticoagulants using a check sheet. Journal of Pharmaceutical Health Care and Sciences, 2021, 7, 22.	0.4	0
4	Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12535.	1.0	2
5	Anticoagulants and Antiplatelet Drugs. , 2021, , .		0
7	Effectiveness and Safety of Idarucizumab for Periprocedural Cardiac Tamponade After Catheter Ablation of Atrial Fibrillation in Dabigatran Recipients: A Retrospective Controlled Study. American Journal of Cardiovascular Drugs, 0, , .	1.0	0
8	Standard operating procedure for idarucizumab reversal of dabigatran anticoagulation in ischemic and hemorrhagic stroke. Journal of Thrombosis and Thrombolysis, 2023, 55, 506-518.	1.0	1